Switching from pembro Q3W to Q6W dosing was also significantly more common at the CS. Further work is needed to clarify the patient, provider, and institutional factors influencing differences in pembro dosing patterns in real-world practice, as well as the impact of dosing patterns on care ...
The Q6W dosing schedule provides an opportunity to reduce the number of infusions required over the treatment course, thereby decreasing time and costs for health care providers, patients and their caregivers. This study quantified the potential infusion episode-related benefits of pembrolizumab Q6W ...
9545#Background:The KEYNOTE-555 trial demonstrated similar efficacy and safety profile of 6-week (q6w) pembrolizumab (400 mg/m2) vs 3-week (q3w) in unresectable and metastatic melanoma leading to FDA's approval of this dosing schedule for adults in 2020. Limited real-world data is ...
This dosing regimen was later replaced by the currently approved flat-dosing (200 mg Q3W or 400 mg Q6W) in all indications, potentially increasing drug use. This retrospective observational study evaluates differences in pembrolizumab use for different dosing strategies in a real-world patient cohort...
Pembro 400 mg Q6W had no new safety concerns, confirming Q6W dosing in hematologic indications.Clinical trial information: NCT04875195.R/R cHLN = 60R/R PMBCLN = 6ORR, n (%) [95% CI]39 (65.0) [51.6, 76.9]3 (50.0) [11.8, 88.2]CR20 (33.3)2 (33.3)PR19 (31.7)1 (16.7)Median*...
Grade 3 TRAEs were observed in 5 subjects: 1 G3 diarrhea (6 mpk, 16.7%), 1 G3 adrenal insufficiency (10 mpk Q6W, 5.9%), 1 each G3 pancreatitis, blurred vision and lipase increase (10 mpk Q3W, 12.5%); all TRAEs occurred after repeat dosing. For the MSS CRC expansion cohort, 7 ...
Q6W pembrolizumab dosing schedule in real-world patients with NSCLC to confirm the expectations of pharmacokinetic modeling. 2. Methods A retrospective study of patients with stage IV NSCLC and PDL1 ≥50% who were treated with first-line pembrolizumab monotherapy at BC Cancer in British Columbia (...